Skip to Main Content

Paper Details

Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.
Clin Cancer Res
50
2018
Checkpoint Kinase 1, Patients, Prexasertib, SCC, SCC of the anus, SCC of the head and neck, SCCHN, Squamous Cell Carcinoma, advanced SCC, advanced squamous cell carcinoma, checkpoint kinase 1, febrile neutropenia, genes, neutropenia, patients, prexasertib, sqNSCLC, squamous cell non-small cell lung cancer, tumor, tumors
Author NameAffiliation
Funda Meric-BernstamThe University of Texas MD Anderson Cancer Center
Wei Zhang
Wei Zhang
  • 1 - 3

Datasets

Release 1.2